A. Ladha

发表

Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all ‘non-adverse’ risk AML

M. Liedtke, L. Muffly, J. Gotlib, 2021, Leukemia & lymphoma.

Mantle cell lymphoma and its management: where are we now?

E. Epner, A. Ladha, J. Pu, 2019, Experimental Hematology & Oncology.

Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML

M. Liedtke, L. Muffly, J. Gotlib, 2020 .

Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin

L. Muffly, G. Mannis, A. Ladha, 2020, Leukemia & lymphoma.

The health seeking behaviour of elderly population in a poor-urban community of Karachi, Pakistan.

S. Saleem, Waleed T. Kayani, A. Malik, 2009, JPMA. The Journal of the Pakistan Medical Association.

Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.

K. Woan, G. Yaghmour, A. Ladha, 2022, Transplant immunology.

A reappraisal of the role of Gram's stains of tracheal aspirates in guiding antibiotic selection in the surgical intensive care unit.

N. Namias, M. Mckenney, D. Sleeman, 1998, The Journal of trauma.

Primary renal lymphoma.

G. Haider, A. Ladha, 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.

D. Miklos, R. Negrin, L. Muffly, 2021, Transplantation and cellular therapy.

Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone

T. Gentile, A. Ladha, Yelena Fudym, 2017, Journal of hematology.

Hepatitis C antibodies in haemodialysis and pattern of end-stage renal failure in Gassim, Saudi Arabia.

A. Ladha, R. Sing, A. R. A. Abdel Rahman, 1996, African journal of medicine and medical sciences.

Presentation and Features of Conversion disorder at a Tertiary Care Hospital in Karachi

H. Naqvi, A. Malik, A. Ladha, 2006 .

Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.

I. Aldoss, L. Muffly, B. Shah, 2023, Journal of Clinical Oncology.

Unique challenges to diagnosing sweet syndrome following induction chemotherapy for relapsed Acute Myeloid Leukemia (AML): A case and brief-review

G. Yaghmour, A. Ladha, E. Tam, 2023, Respiratory medicine case reports.

What is the Personal Immune Price for Hospice Caregivers? A Case-Control Study.

R. Vierkant, W. Nevala, J. Kaur, 2018, Archives of palliative care and medicine.